Vendor, San Mateo, CA
Revagenix Inc.
UEI D98QFZUPFXJ9, CAGE 8B1Y9
2 awards and $0 obligated between July 1, 2026 and July 10, 2026, 100% under full and open competition, against 21.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93020C00018Definitive Contract, July 10, 2026, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Select a Novel Small Molecule Antibiotic for Clinical Development and Advance IT Through Ind Filing and Phase 1 Clinical Studies.NAICS 541715, PSC AN12 | $0 |
| 75N93022C00061Definitive Contract, July 1, 2026, Full and Open Competition, 30 offers | National Institutes of Health NiaidNational Institutes of Health | EO14398 a Novel LPXC Inhibitor with Pan-Resistant Pseudomonas and Burkholderia Activity.NAICS 541715, PSC AN12 | $0 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 3 across 2 awards